IL-8在三阴性乳腺癌中的差异性表达及其临床意义

Differential expression of IL-8 in triple negative breast cancer and its clinical significance

目的探讨IL-8在三阴性乳腺癌(triple negative breast cancer,TNBC)中的表达水平及其与患者临床病理特征以及预后之间的关系。方法通过免疫组化染色检测80例TNBC患者肿瘤组织中IL-8蛋白的表达水平,并分析IL-8蛋白表达水平与TNBC患者临床病理特征及预后之间的关系。结果80例TNBC患者中,IL-8蛋白呈高表达者占比22.5%(18/80)。IL-8蛋白在TNBC肿瘤组织中的表达水平与肿瘤T分期、临床分期、Ki-67表达情况、WHO分级以及淋巴结转移情况具有相关性(P<0.05),但与患者年龄、绝经状态、肿瘤病理类型和是否接受过新辅助化疗均无关(P>0.05)。log-rank检验结果显示,IL-8蛋白高表达组的无病生存情况差于IL-8低表达组(P<0.05)。多因素Cox比例风险回归模型分析结果显示,IL-8蛋白的表达水平是影响TNBC患者预后的独立风险因素[HR=1.180,95%CI为(1.001,1.391),P=0.049],IL-8蛋白高表达的TNBC患者的预后较差。结论IL-8的表达水平是影响TNBC患者预后的独立风险因素。

Objective To investigate the relationship between the expression of IL-8 protein in triple negative breast cancer(TNBC)and clinicopathological features and survival prognosis.Methods The expression of IL-8 protein in 80 cases of TNBC was detected by immunohistochemical staining,and the relationship between the expression of IL-8 protein and clinicopathological features and prognosis of TNBC patients was analyzed byχ2 test,log-rank test,and Cox proportional hazards regression.Results In 80 TNBC patients,the high expression of IL-8 protein accounted for 22.5%(18/80).The expression level of IL-8 protein in TNBC tumor tissue was correlated with T stage,clinical stage,Ki-67 expression,WHO grade and lymph node metastasis(P<0.05).However,it was not related to age,menopausal status,pathological type of tumor and whether they had received neoadjuvant chemotherapy(P>0.05).The results of log-rank analysis showed that the disease-free survival rate(DFS)of high expression group of IL-8 protein was poor than that of low expression group of IL-8 protein(P<0.05).Multivariate Cox proportional hazards regression analysis showed that the expression of IL-8 protein was an independent factor affecting the survival and prognosis of TNBC patients[HR=1.180,95%CI(1.001,1.391),P=0.049].The prognosis of TNBC patients with high expression of IL-8 protein was poor.Conclusion The expression level of IL-8 protein is an independent risk factor affecting the survival and prognosis of patients with TNBC.